Peculiar Cytological Cerebrospinal Fluid Pattern in a Case of Encephalomyelitis During Anti-Tumor Necrosis Factor-α Therapy by unknown
CASE REPORT
Peculiar Cytological Cerebrospinal Fluid Pattern
in a Case of Encephalomyelitis During Anti-Tumor
Necrosis Factor-a Therapy
Yana Motuzova • Alessia Di Sapio • Marco Capobianco • Arianna Sala •
Fabiana Marnetto • Simona Malucchi • Antonio Bertolotto
To view enhanced content go to www.neurologytherapy-open.com
Received: October 27, 2014 / Published online: March 6, 2015
 The Author(s) 2015. This article is published with open access at Springerlink.com
ABSTRACT
Introduction: Tumor necrosis factor-a (TNF-a)
blocking agents may be associated with
neurological adverse events, including
demyelinating syndromes, that can be difficult
to differentiate from multiple sclerosis (MS) and
clinically isolated syndrome (CIS) as neither the
clinical nor laboratory distinctive features have
been reported. Usually clinicians mainly
examine the diagnostic value of
immunoglobulin G oligoclonal bands
underestimating the value of other
cerebrospinal fluid (CSF) parameters (such as
CSF cytology).
Case Report: We present a case of a patient
who acutely developed mild pyramidal and
sensory impairment of lower limbs and
urinary hesitancy during treatment with
adalimumab, a monoclonal antibody to TNF-a,
for psoriatic arthritis. Magnetic resonance
imaging demonstrated a widespread area of
hyperintense signal extending from C5 to D8
level in T2-weighted images. Two consecutive
CSF examinations showed an intense activation
of monocyte/macrophage lineage (88% and
90%, respectively) with some giant and
binucleated cells that notably decreased five
months after TNF-a blocker cessation. We
compared the results of CSF examinations of
our patient with CSF results of 20 patients with
MS and 20 patients with CIS that demonstrated
activation of both lymphocytic and monocytic
lineage (MS: 48% and 52%, respectively, CIS:
54.5% and 43.5%, respectively) that were very
different from the findings in
adalimumab-related encephalomyelitis in
acute phase (11% and 89%, respectively). CSF
cytology in two patients with neuromyelitis
optica during the relapse (n = 3) showed minor
monocyte/macrophage activation (9%) and an
increased number of granulocytes (77%).
Conclusion: Prominent activation of
monocyte/macrophage lineage with some
binucleated giant cells in CSF could be
induced by anti-TNF-a treatment. The peculiar
CSF pattern, never found in MS, CIS, and NMO,
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can help in differential diagnosis and stresses
the importance of careful CSF cytology
evaluation in the course of demyelinating
diseases.
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INTRODUCTION
Tumor necrosis factor-a (TNF-a) plays an
important role in many aspects of immune
system development, immune-response
regulation, and T cell-mediated tissue injury,
and is involved in many pathological
conditions [1]. TNF-a inhibition represents a
significant advance in the treatment of
rheumatoid arthritis, and is approved for the
treatment of ankylosing spondylitis and
psoriatic arthritis, as well as Crohn’s disease
and ulcerative colitis [1].
Tumor necrosis factor-a blocking agent
adverse events include peripheral and central
nervous system (CNS) demyelination [1–8];
however, the role of anti-TNF-a drugs in the
development of demyelination has not yet been
well defined. It is still a matter of debate
whether TNF-a blocking agents could cause de
novo nervous system demyelination or unmask
latent disease, or whether the use of these drugs
and the development of neurological disorders
is coincidental [9, 10]. Any clinical, biological,
or radiological evaluation can differentiate
these conditions that have different prognosis
and treatment. Here, we present a case of a
patient who acutely developed mild pyramidal
and sensory impairment of lower limbs and
urinary hesitancy during treatment with
adalimumab, a monoclonal antibody to TNF-a,
for psoriatic arthritis.
CASE REPORT
Informed consent was obtained from the patient
for being included in the study. A patient came to
the authors’ attention complaining of gait
impairment and lower limb hypoesthesia,
rapidly ascending up to the base of the neck,
with dysesthesia and urinary hesitation.
Symptoms had begun after the third injection of
adalimumab, a recombinant human
immunoglobulin (Ig) G1 monoclonal antibody
that selectively binds TNF-a and blocks its
interaction with the p55 and p75 cell surface
TNF receptors [1], thatwas prescribed for psoriatic
arthritis. Neurological examination showed mild
proximal weakness at the lower limbs and mild
hypopallesthesia at the left lower limb.
The patient underwent brain and spinal
magnetic resonance imaging (MRI): T2-
weighted images showed a widespread area of
hyperintense signal extending from C5 to D8
level and a clinically silent brain lesion adjacent
to the left trigonum (Fig. 1). Spinal cord
diameters were slightly increased, mostly at
C5–C7 levels (Fig. 1). Both brain and spinal
cord lesions were hyperintense on T1-weighted
images after contrast enhancement.
The patient underwent serological
examinations (immuno-rheumatological,
thrombophilic, virological screening, and
venereal disease research laboratory tests) that
did not show any abnormalities. Immuno-
rheumatological tests included: erythrocyte
sedimentation rate, C3, C4, rheumatoid factor,
IgG, IgA, IgM, antinuclear antibodies,
extractable nuclear antibodies, anti-neutrophil
cytoplasmatic antibodies, anti-double-stranded
DNA antibodies, anti-tissue antibodies,
54 Neurol Ther (2015) 4:53–60
anti-endomysium antibodies, anti-
transglutaminase antibodies, anti-gliadin
antibodies, and anti-liver–kidney microsomal
antibodies. Thrombophilic tests included: anti-
beta 2 glycoprotein 1 antibodies, anti-
cardiolipin antibodies, lupus anticoagulant
antibodies, activated protein C resistance,
protein C, protein S total, and
omocisteinemia. Virological screening and
venereal disease research laboratory tests
included: anti-HIV, anti-hepatitis A virus
(HAV), anti-hepatitis C virus (HCV), anti-
hepatitis B virus (HBV) antibodies, hepatitis B
surface antigen (HbsAg), venereal disease
research laboratory test, anti-toxoplasma
antibodies (IgM, IgG), anti-cytomegalovirus
(CMV) antibodies (IgM, IgG), anti-viral-capsid
antigen (VCA) antibodies (IgM, IgG), anti-
herpes simplex virus (HSV) 1 and 2 antibodies
(IgM, IgG), and anti-varicella zoster virus (VZV)
antibodies (IgM, IgG).
Two consecutive CSF examinations were
performed: glucose and protein levels, and IgG
index were in normal ranges, whereas cell count
(45 and 43 cells/lL, respectively) and blood–CSF
barrier permeability index (11.3 and 10.5,
respectively) were increased. Oligoclonal bands
were negative in both samples. A great number of
activated cells of monocyte/macrophage lineage
were present (88% and 90%, respectively), often
forming large clusters. Prominent nucleoli were
present in the majority of the clustered cells
(Fig. 2a). Moreover, some huge cells with
irregular cellular membrane and eosinophilic,
vacuolated cytoplasm were detected. Several
cells showed a big kidney-shaped nucleus;
notably a few cells presented two nuclei (Fig. 2b).
Polymerase chain reaction (PCR) for HSV-1,
HSV-2, VZV, and CMV was negative both in
serum and CSF. Tuberculosis reactivation and
meningeal carcinomatosis were excluded by
X-ray of the chest, colonoscopy, serum
neoplastic markers evaluation, and appropriate
CSF examination. Neoplastic markers
evaluation included alpha-fetoprotein,
prostate-specific antigen, carcinoembryonic
antigen, cancer antigen 19.9, cancer antigen
125, and cancer antigen 15.3. Peripheral blood
lymphocyte typing was normal.
The patient underwent high-dose
intravenous steroid therapy for 5 days with
regression of dysesthesia. CSF examination was
performed two more times, the last one,
5 months later: cell count progressively
decreased (7 cells/lL), with the reduction of
monocyte/macrophage lineage (47%), but rare
giant cells were still present at the last
examination. Blood–CSF barrier permeability
index was slightly increased (9.6). During the
follow-up, a test for anti-aquaporin antibodies
was performed that did not reveal their
presence in serum.
Neuroradiological follow-up did not show
any spinal abnormality 4 months after
symptoms onset, when both spinal diameter
and signal intensity returned normal. Six
months after onset of disease, the patient only
Fig. 1 Brain and spinal magnetic resonance imaging. T2-
weighted images showed a widespread area of hyperintense
signal extending from C5 to D8 level and a clinically silent
brain lesion adjacent to left trigonum. Spinal cord
diameters were slightly increased, mostly at C5–C7 levels
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complained of paraesthesia at foot level and
very mild urinary hesitation. After 7 years of
follow-up, the patient only complains of very
mild dysesthesia; repeated brain and spinal MRI
examinations were normal.
The prominent monocyte/macrophage
lineage activation found in CSF of this case
prompted us to compare CSF cytology
examinations of our patients with those of
multiple sclerosis (MS), clinically isolated
syndrome (CIS), and neuromyelitis optica
(NMO). The last 20 CSF cytological
examinations of MS and CIS and 3 cases of
NMO were compared with the 3 lumbar
punctures performed in our patient (Table 1).
Cerebrospinal fluid analysis demonstrated
the same degree of activation of both
lymphocytic and monocytic lineage in MS and
CIS group (MS: 48% and 52%, respectively, CIS:
54.5% and 43.5%, respectively; Fig. 2c), that
was quite different from the findings in
adalimumab-related encephalomyelitis in
acute phase (11% and 89%, respectively),
characterized by prominent activation of
monocyte/macrophage lineage. There was no
statistically significant difference in CSF
parameters between patients with MS in
relapse and remission (analyses were carried
out using R version 3.1.1). CSF cytology in two
patients with NMO during the relapse (n = 3)
Fig. 2 CSF cytological analysis. a A large cluster of
activated lymph monocyte, with prominent nucleoli. b A
giant cell, showing two big kidney-shaped nuclei, with
irregular cellular membrane and eosinophilic, vacuolated
cytoplasm. c CSF examination during relapse of multiple
sclerosis shows activation of lymphocytic lineage. d CSF
examination during acute phase of neuromyelitis optica
shows high levels of granulocytes. CSF Cerebrospinal ﬂuid
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showed minor monocyte/macrophage
activation (9%) and increased number of
granulocytes (77%; Fig. 2d).
DISCUSSION
Tumor necrosis factor-a, secreted by microglia
and macrophages, has a critical role in
demyelination [11]. A clinical trial in 1999
showed a worsening of the course in patients
with MS during anti-TNF-a treatment [12].
Subsequently, central or peripheral nervous
system demyelination was recognized as a
well-known adverse event of anti-TNF-a
therapy [1–8]. In 2013, the Food and Drug
Administration Adverse Event Reporting System
documented 772 cases of demyelinating
diseases related to TNF-a antagonists,
including 167 cases related to adalimumab [10].
Tumor necrosis factor-a blocking agents
could cause de novo nervous system
demyelination or unmask latent disease, or the
use of these drugs and the development of
neurological disorders could be coincidental.
Neither clinical nor laboratory distinctive
features have been reported to differentiate
demyelinating diseases related to TNF-a
antagonists from other CNS demyelinating
diseases. In fact, brain and spinal MRI usually
show areas of hyperintensities in T2-weighted
images with or without gadolinium
enhancement on T1-weighted images that are
not helpful in differentiation between
demyelination due to anti-TNF-a treatment
and underlying MS and CIS. CSF examination
received very little attention and any distinctive
CSF pattern was not reported to distinguish
between CIS/MS and TNF-a induced CNS
lesions. A detailed CSF examination was
reported only in few cases and mainly focused
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and IgG index [3, 4, 7]. To the best of our
knowledge, CSF cytology has not been reported.
In our case, CSF cytology showed a pattern
that was different from CIS, MS, and NMO,
being characterized by a great number of
activated cells of monocyte/macrophage
lineage with large kidney-shaped nucleus (88%
and 90%, respectively, in two subsequent CSF
analyses during the acute phase), often forming
large clusters with lymphocytes; moreover, a
few cells were binucleated. This pattern was
clearly different from both CIS and MS that
showed a similar increased percentage and
activation of both lymphocyte and monocyte
lineages. NMO is characterized, during acute
phase of the disease, by the presence of
granulocytes [13]. Moreover, in any of the 42
cases of CIS, MS, and NMO we found
binucleated giant cells as in the adalimumab-
related CNS inflammation.
The presence of binucleated cells in CSF can
suggest a neoplastic origin and prompt testing
for cellular expression or molecular tumoral
markers. In the present case, the binucleated
cells were not been assessed in regard to
expression markers or molecular biology
because the patient had two lesions, one in the
spinal cord and one in the brain; bifocal lesions
are very rarely of tumoral origin [14]. Besides,
neoplastic origin for the binucleated cells was
excluded by the negativity of the examinations
performed to find a primary tumor, by the
progressive reduction of the giant cells in the
last lumbar puncture performed 5 months after
the cessation of adalimumab, and by the
absence of any neoplasia during 7 years of
follow-up. A non-oncological origin of
binucleated cells in CSF is the fusion of
monocyte/macrophages, a well-known
phenomenon occurring during granulomatous
and herpetic infection [15], that in our patient
were excluded by negativity of both viral PCR
detection and tuberculosis tests. In theory, the
presence of binucleated cells would also require
bone-marrow assessment, but this was not
performed as CNS tumors in the course of anti-
TNF therapy have never been reported [11, 16].
The mechanism causing the peculiar CSF
pattern in our patient, that is a prominent
activation of monocyte lineage, with increased
number of macrophages and their fusion into
binucleated cells during adalimumab
treatment, is unknown; however, some data
suggest an involvement of the CD36 receptor
expressed on monocytes and a direct role of the
monoclonal anti-TNF-a antibody [15, 17]. In
fact it has been demonstrated that, while TNF-a
inhibits, on the contrary, adalimumab increases
CD36 membrane expression on human
monocytes [17] and CD36 can cause
macrophages fusion [15].
The 7 years of follow-up without a second
CNS inflammatory involvement, the absence of
oligoclonal bands in CSF, the progressive
attenuation of the symptoms, and the normal
spinal cord and brain MRI performed during the
follow-up strongly suggest that the CNS lesions
were a single acute episode caused by the
treatment with adalimumab, that did not
unmask a preclinical demyelinating disease
and was not triggered MS.
CONCLUSION
Our case indicates that CSF cytological
examination must be included in the study of
CNS adverse events occurring in anti-TNF-a-
treated patients. Further CSF cytological
examinations in patients with similar clinical
conditions will establish if the finding of
prominent activation of
monocyte/macrophage lineage with
binucleated CSF cells is a hallmark of this
clinical condition, allowing for the distinction
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between a demyelinating chronic disease and a
single inflammatory episode, remitting with the
withdrawal of the anti-TNF-a treatment.
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